rV-NY-ESO-1: Phase II data

Researchers at the institute and colleagues reported data from a U.S. Phase II trial in 22 epithelial ovarian cancer patients with NY-ESO-1-expressing tumors showing that vaccination with rV-NY-ESO-1 ...